恒瑞医药: 恒瑞医药关于股份回购实施结果暨股份变动的公告

Core Points - The company has completed its share repurchase plan, acquiring a total of 12,905,144 shares, which represents 0.20% of the total share capital [2][4] - The repurchase was conducted at a price range of 39.00 to 57.01 RMB per share, with an average price of approximately 46.59 RMB per share, totaling 601.27 million RMB [2][3] - The repurchased shares will be used for an employee stock ownership plan, aimed at enhancing the alignment of interests between the company, shareholders, and employees [3][5] Summary of Repurchase Plan - Initial announcement date of the repurchase plan was May 16, 2024, with a total budget of 600 million to 1.2 billion RMB and a maximum repurchase price of 67.38 RMB per share [1] - The repurchase period was set for 12 months following the board's approval [1] - The actual repurchase amount exceeded the lower limit of the planned budget but remained within the upper limit [2] Impact of Share Repurchase - The share repurchase will not significantly affect the company's operational activities or financial status [2] - There will be no change in control or compliance with listing conditions as a result of the repurchase [2] Shareholding Changes - Before the repurchase, the total number of shares was 6,379,002,274, and this number remains unchanged post-repurchase [4] - The repurchased shares will be allocated to the employee stock ownership plan within 36 months [5]